Celldex Therapeutics, Inc. (CLDX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-01-06

Key Insights

Samuel Bates Martin, the SVP and CFO of Celldex Therapeutics, Inc. (CLDX), exercised 4,817 stock options at $10.38 per share on January 2, 2026, increasing his direct ownership in the company to 32,942 shares.
The stock options were part of an incentive compensation plan that was fully vested as of June 18, 2024, indicating a long-term alignment between the CFO and shareholders.
The transaction suggests the CFO's confidence in the company's prospects, as he has chosen to hold on to the shares rather than sell them immediately.

Want the newest filings?

This analysis covers the filing from 2026-01-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Celldex Therapeutics, Inc.

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.